China NMPA Product Recall - SynchroMed II/EL

Medtronic Inc. initiated a voluntary recall of its SynchroMed II and SynchroMed EL implantable drug infusion pumps in response to multiple reports of "bag infusion" problems. Overseen by the National Medical Products Administration (NMPA), the recall addressed critical safety concerns where the devices delivered either an overdose or insufficient dosage of medication. From May 1996 to September 2010, Medtronic received 351 global reports of malfunctions, including 8 deaths and 270 cases requiring significant medical intervention due to serious or life-threatening injuries. Overdose events could cause immediate or delayed severe symptoms, particularly with baclofen. Conversely, insufficient dosage led to treatment interruption, symptom resurgence, or dangerous withdrawal effects, also life-threatening for baclofen patients. Medtronic (China) Co., Ltd. began notifying healthcare professionals on January 24, 2011, completing the process by February 25, 2011. Required actions included in-person doctor notifications to explain the recall's background and details. Additionally, Medtronic committed to updating both the Prescriber Information Handbook and Patient Handbook for its implantable drug infusion systems to clearly describe the risks of insufficient dosage, aiming to enhance patient safety and ensure appropriate device use.